PWM
AERI

Perigon Wealth Management’s Aerie Pharmaceuticals AERI Stock Holding History

Perigon Wealth Management’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,098
Closed -$60K – 645
2018
Q1 		$60K Hold
1,098
– – 0.02% 289
2017
Q4 		$66K Hold
1,098
– – 0.02% 257
2017
Q3 		$53K Buy
+1,098
New +$59.9K 0.02% 330

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Perigon Wealth Management's AERI Position: Q2 2018 in Review

Perigon Wealth Management sold out of Aerie Pharmaceuticals (AERI) in Q2 2018, closing a stake of 1,098 shares — an estimated $60K sold.

Perigon Wealth Management first reported a position in AERI in Q3 2017 and held it in 3 quarters. The position peaked at $66K in Q4 2017. 175 funds tracked by Wall St. Rank hold AERI as of Q2 2018.

  • Perigon Wealth Management reported no remaining Aerie Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Perigon Wealth Management sold 1,098 Aerie Pharmaceuticals shares in Q2 2018, an estimated $60K.
  • Perigon Wealth Management first reported a position in Aerie Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Perigon Wealth Management's Aerie Pharmaceuticals position peaked at $66K in Q4 2017.
  • 175 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2018.

Based on Perigon Wealth Management's 13F filing for Q2 2018, filed 7 Aug 2018.